<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81930">
  <stage>Registered</stage>
  <submitdate>27/03/2007</submitdate>
  <approvaldate>12/04/2007</approvaldate>
  <actrnumber>ACTRN12607000201471</actrnumber>
  <trial_identification>
    <studytitle>An investigation of the safety and effect of ACV1 on neuropathic pain in patients with diabetic peripheral neuropathic pain or post-herpetic neuralgia.</studytitle>
    <scientifictitle>A randomised, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of subcutaneous doses of ACV1 in patients with diabetic peripheral neuropathic pain or post-herpetic neuralgia.</scientifictitle>
    <utrn />
    <trialacronym>N/A</trialacronym>
    <secondaryid>ACV103</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetic peripheral neuropathy (DPN).</healthcondition>
    <healthcondition>Post-herpetic neuralgia (PHN).</healthcondition>
    <healthcondition>Post-herpetic neuralgia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients will receive ACV1 at a dose of 0.4 mg/kg, injected subcutaneously once per day for 21 days.</interventions>
    <comparator>Patients will receive placebo, injected subcutaneously once per day for 21 days.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the safety and tolerability of ACV1.</outcome>
      <timepoint>Laboratory testing at screening, pre-dose on Day 1 to Day 21 of treatment, and 7 days post-treatment. </timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Vital sign monitoring</outcome>
      <timepoint>At screening, pre-dose, 30 minutes and 1 hour post-dose on all treatment days. On Day 1 and 21 of treatment, vital signs will also be monitored at 2, 4 and 8 hours post-dose.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Electrocardiogram testing</outcome>
      <timepoint>Pre-dose, and at 2 and 4 hours post-dose on Day 1 and 21 of treatment; 7 days post-treatment.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To determine the effect of ACV1 on pain rated using a visual analogue score (VAS).</outcome>
      <timepoint>During screening; pre-dose, 30 minutes, 1, 2, 4, and 8 hours post-dose on Day 1 of treatment; pre-dose and 1 hour post-dose on Days 2 to 20 of treatment; pre-dose, 30 minutes, 1, 2, 4, and 8 hours post-dose on Day 21 of treatment; 7 days post-treatment.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To determine the effect of ACV1 on pain using a sleep interference score. </outcome>
      <timepoint>During screening; pre-dose on Day 1 to 21 of treatment; 7 days post-treatment.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To determine the long-term effect of ACV1 on pain using a Short Form McGill Pain Questionnaire (SF-MPQ).</outcome>
      <timepoint>Pre-dose on Days 1 and 21 of treatment.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To determine the long-term effect of ACV1 on pain using a Neuropathic Pain Symptom Inventory (NPSI).</outcome>
      <timepoint>Pre-dose on Days 1 and 21 of treatment.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To determine the long-term effect of ACV1 on pain using the Clinician Global Impression of Change (CGIC) and the Patient Global Impression of Change (PGIC).</outcome>
      <timepoint>Post-dose on Day 21 of treatment.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To determine the effect of ACV1 on touch sensitivity using von Frey filaments.</outcome>
      <timepoint>Pre-dose and at 30 minutes, 1, 2, 4, and 8 hours post-dose on Days 1 and 21 of treatment.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To determine the single and multiple dose subcutaneous pharmacokinetics of ACV1.</outcome>
      <timepoint>Pre-dose and 10, 15, 20, 30, and 45 minutes post dose, and 1, 1.5, 2, 2.5, 3, 4, 6 and 8 hours post-dose on Days 1 and 21 of treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>'Nil'</outcome>
      <timepoint>'Nil'</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Stable and controlled (haemoglobin A1c level less than 9.0% at screening) Type I or Type II diabetes mellitus, reporting at least 3 months of pain (VAS = 4cm for at least 5 days a week) due to DPN. OR, diagnosis of PHN, reporting at least 3 months of pain (VAS = 4cm for at least 5 days a week) since shingles vesicle crusting.Ability to provide written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Cardiac abnormality.Hypotension or hypertension.Organ dysfunction.Pain anywhere else of an equal or greater intensity of the neuropathic pain.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes.</concealment>
    <sequence>A computer generated randomisation scheme will be produced by the trial statistician.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>All site and sponsor staff (staff administering the treatments, staff assessing the outcomes and staff analysing the results) and all subjects will be blinded to the study, with the exception of the trial pharmacist who will prepare the drug in a manner that maintains the blinding for all other staff.</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>10/04/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3128</postcode>
    <postcode>4029</postcode>
    <postcode>2065</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Metabolic Pharmaceuticals Ltd.</primarysponsorname>
    <primarysponsoraddress>Level 3, 509 St Kilda Rd
Melbourne 3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Metabolic Pharmaceuticals Ltd.</fundingname>
      <fundingaddress>Level 3, 509 St Kilda Rd
Melbourne 3004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A.</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Neuropathic pain is a debilitating form of chronic pain that arises from nerve damage. Current treatments for neuropathic pain can have undesirable side-effects and are limited in their effectiveness.
ACV1 is a small synthetic drug designed from a component of the venom of an Australian marine cone snail, and is being developed as a treatment for neuropathic pain.
The aim of this study is to investigate whether ACV1 provides pain relief to patients with diabetic peripheral neuropathy or post-herpetic neuralgia.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Sydney Central Coast Area Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Research Office
Level 4, Vindin House
Royal North Shore Hospital
Pacific Hwy, St Leonards
NSW 2065</ethicaddress>
      <ethicapprovaldate>5/04/2007</ethicapprovaldate>
      <hrec>0612-249M</hrec>
      <ethicsubmitdate>26/03/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Eastern Health Research and Ethics Committee</ethicname>
      <ethicaddress>Level 2, Clive Ward Building
16 Arnold St
Box Hill VIC 3128</ethicaddress>
      <ethicapprovaldate>17/05/2007</ethicapprovaldate>
      <hrec>103/0607</hrec>
      <ethicsubmitdate>24/04/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane Hospital Human Rssearch Ethics Committee</ethicname>
      <ethicaddress>Level 7, Block 7
Royal Brisbane and Women's Hospital
Butterfield St
Heston QLD 4029</ethicaddress>
      <ethicapprovaldate>19/03/2007</ethicapprovaldate>
      <hrec>2007/027</hrec>
      <ethicsubmitdate>9/02/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Upper South A Regional Ethics Committee</ethicname>
      <ethicaddress>4th Floor, 250 Oxford Terrace
PO Box 3877
Christchurch</ethicaddress>
      <ethicapprovaldate>18/04/2007</ethicapprovaldate>
      <hrec>URA/07/02/011</hrec>
      <ethicsubmitdate>12/03/2007</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Michael Cousins</name>
      <address>Pain Management &amp; Research Centre
Level 9C
Main Block
Royal North Shore Hospital
St Leonards NSW 2065</address>
      <phone>+ 61 2 99266451</phone>
      <fax>+ 61 2 99266548</fax>
      <email>MCousins@nsccahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Caroline Herd</name>
      <address>Metabolic Pharmaceuticals Ltd
Level 3
509 St Kilda Rd
Melbourne VIC 3004</address>
      <phone>+ 61 3 98605700</phone>
      <fax>+ 61 3 98605777</fax>
      <email>caroline.herd@metabolic.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lyndal Borrell</name>
      <address>Metabolic Pharmaceuticals Ltd
Level 3 509 St Kilda Rd
Melbourne 3004</address>
      <phone>+ 613 9860 5700</phone>
      <fax>+613 9860 5777</fax>
      <email>lyndal.borrell@metabolic.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>